Raloxifene is a selective estrogen receptor modulator (SERM) used primarily in women's health to protect bone health after menopause. It is available as a 60 mg oral pill and is marketed in many regions under brand names such as Evista. In Hong Kong, raloxifene is a prescription-only medication regulated by the Hong Kong Department of Health.
These indications are approved by major regulatory agencies, including the U.S. FDA, the European EMA, and are recognized by the Hong Kong Department of Health.
Off-label use requires careful medical supervision and individualized risk assessment.
These effects are usually transient and may lessen with continued therapy.
A black-box warning highlights the risk of VTE and stroke; patients should seek immediate medical attention for sudden leg pain, swelling, shortness of breath, or chest pain.
If you are taking any prescription, over-the-counter, or herbal products, discuss them with your pharmacist or physician before starting raloxifene.
Dose adjustments are not routinely required for renal or hepatic impairment, but severe organ dysfunction warrants clinical judgment.
This article provides educational information about raloxifene and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Rising calcium intake can lower raloxifene absorption. To maximise effectiveness, take raloxifene at least two hours apart from calcium-containing products or multivitamins with iron.
Unlike estrogen therapy, raloxifene does not stimulate breast or uterine tissue, reducing the risk of estrogen-dependent cancers while still protecting bone.
Smoking increases cardiovascular and thrombotic risks. Women who smoke should discuss these concerns with their clinician before initiating raloxifene.
Sudden swelling, pain, or redness may indicate a deep-vein thrombosis. Seek immediate medical attention; early treatment reduces complications.
Raloxifene may modestly lower LDL-cholesterol and raise HDL-cholesterol, but it is not prescribed primarily for lipid management.
Yes, but keep the medication in its original packaging with a copy of the prescription. Some countries may require a doctor’s note for controlled substances; raloxifene is not a controlled drug but remains prescription-only.
Weight changes are not a common side effect. Any noticeable weight fluctuation should be evaluated to rule out other causes.
Significant increases in BMD are generally observed after 12 months of consistent therapy, though fracture risk reduction may begin earlier.
St. John’s wort (a CYP3A4 inducer) may reduce raloxifene levels, potentially diminishing its bone-protective effect. Discuss all herbal products with your healthcare provider.
In most markets, the 60 mg tablet is round, white, and bears the imprint “RAL-60” (or a similar code). Appearance can vary by manufacturer; always verify with your pharmacist.
